Thermo Fisher Scientific to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024
Jefferies Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Raises Target Price to $670
Express News | Wells Fargo Initiates Coverage On Thermo Fisher Scientific With Overweight Rating, Announces Price Target of $670
Thermo Fisher Scientific Inc. (TMO): Among Morgan Stanley's Highest Conviction Stocks
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
RNAi Market and Technologies Industry Report 2024, With Company Profiles of Major Players Including Alnylam Pharmaceuticals, Novartis, Thermo Fisher Scientific and Revvity
$100 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today
In One Chart | Wall Street Eyes New Sectors for the Next Stock Market Surge
CDMO Executive Says Novo Purchase of Catalent May Help Competition - CTFN
Morgan Stanley's 20 Top Stock Picks
Thermo Fisher Scientific's (NYSE:TMO) Investors Will Be Pleased With Their Solid 127% Return Over the Last Five Years
Mega-Cap Tech Stocks Still Make up Core of Hedge Funds' Top Positions, Analysis Shows
Thermo Fisher Scientific Stock: Analyst Estimates & Ratings
Thermo Fisher Scientific Innovations Achieve R&D 100 Awards, Including Special Recognition Market Disruptor
We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt
Thermo Fisher Scientific's Clinical Research Business Recognized by ISG for Digital Services Leadership
Looking Into Thermo Fisher Scientific's Recent Short Interest
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
Life Science Tools and Reagents Market Report 2024, With Profiles of BD, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, Merck, Promega, Qiagen, Revvity, Takara Bio and Thermo Fisher Scientific
Is Thermo Fisher Scientific Inc.'s (NYSE:TMO) Recent Stock Performance Tethered To Its Strong Fundamentals?